Gastrointestinal Drugs Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Application, Route Of Administration, Distribution Channel, and Geography

Description

List of Tables

According to our new research study on "Gastrointestinal Drugs Market Forecast to 2031 -Global Analysis - by Drug Class, Application, Route of Administration, and Distribution Channel," the market is anticipated to grow from US$ 59,713.68 million in 2023 and is projected to reach US$ 106,304.81 million by 2031; it is expected to register a CAGR of 7.3% during 2023-2031. The gastrointestinal drugs market growth is attributed to the increasing prevalence gastrointestinal diseases and increasing developments of biologics for gastrointestinal diseases.

Gastrointestinal drugs are medications specifically designed to treat disorders and conditions affecting the digestive system, which includes the esophagus, stomach, intestines and related organs. These drugs can help manage symptoms, alleviate pain, and treat underlying diseases.

North America accounted for a major share of the global gastrointestinal drugs market in 2023. The North America gastrointestinal drugs market is segmented into the US, Canada, and Mexico. Increasing incidence of gastrointestinal diseases due to change in lifestyle, government support for prevention and treatment of gastrointestinal diseases, presence of well-developed healthcare infrastructure, growing pharmaceutical industry, reimbursement coverage and industry giants are some of the prominent factors propelling the market growth in North America.

In North America, the US is the largest market for gastrointestinal drugs. In the US, the increasing prevalence of gastrointestinal diseases contributes directly to the demand for gastrointestinal drugs. Crohn's disease and ulcerative colitis are two of the most common types of inflammatory bowel diseases (IBD). As per the Crohn's & Colitis Foundation of America (CCFA) report, "Facts about IBD," approximately 70,000 new cases of IBD are diagnosed yearly in the US. The overall prevalence of IBD increased significantly from 2011 to 2020. The study estimates that nearly 1 in 100 Americans have IBD, and ~2.4 million Americans have some form of IBD. Additionally, the rising funding for research and development related to gastrointestinal diseases is expected to increase focus on developing novel treatment medications. Per a study titled "Endometriosis Is Undervalued," published in 2022, Crohn's disease research received US$ 90 million in funding, or US$ 130.07 per patient.

The US Food and Drug Administration (FDA) approvals are likely to support the growth of the market. For instance, in May 2020, the US FDA approved Qinlock (ripretinib) tablets as a fourth-line treatment for advanced gastrointestinal stromal tumors (GIST). In May 2024, Strides Pharma received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the US FDA for the treatment of gastrointestinal diseases as well as stomach ulcers, gastroesophageal reflux disease (GERD), and stomach inflammation and prevent stress ulcers.

Therefore, the growth of this market is driven by the growing prevalence of gastrointestinal diseases, developments by the market players, and the presence of major market players in the US.

Strategic Initiatives in Gastrointestinal Drugs to Provide Market Opportunities in Future

Companies operating in the gastrointestinal drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and improve their capacities to cater to a greater than existing customer base. A few strategic initiatives taken by key players operating in the gastrointestinal drugs market are mentioned below

In September 2023, Vivante Health closed US$ 31 million in a Series B funding round led by Mercato Partners, a new investor, to advance the digital digestive health platform. The new funding is mainly received due to the latest GIThrive platform enhancements that highlight the platform's unique ability to provide proper care at the right time. Series B Capital provides continued technological advancements designed to predict the onset and progression of gastrointestinal conditions and provide complete virtual care.

In May 2024, Strides Pharma Global Pte. Ltd received approval from the US FDA to market the generic version of Sucralfate Oral Suspension, 1gm/10 mL. The medication is used for the treatment of gastrointestinal diseases such as stomach ulcers, GERD, and stomach inflammation, as well as to help avoid stress ulcers.

In May 2023, AbbVie received US FDA approval for RINVOQ (upadacitinib) to treat adults with mild to severe active Crohn's disease having an inadequate response or intolerance to one or more TNF blockers. It is the seventh FDA approval for RINVOQ across rheumatology, dermatology, and gastroenterology, where it is now indicated in both ulcerative colitis and Crohn's disease.

Therefore, strategic initiatives by various companies focusing on the development of drugs for the treatment of digestive diseases are likely to offer growth opportunities to the gastrointestinal drugs market in the coming years.

Gastrointestinal Drugs Market: Competitive Landscape and Key Developments

Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Celltrion Inc, and Pfizer Inc are among the key companies operating in the gastrointestinal drugs market.

The US Food and Drug Administration, International Foundation for Gastrointestinal Disorders, and American college of gastroenterology, and The International Union of Basic and Clinical Pharmacology (IUPHAR) are among the primary and secondary sources referred to while preparing the gastrointestinal drugs market report.

Product Code: TIPRE00014758

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Gastrointestinal Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Gastrointestinal Drugs Market - Key Market Dynamics

5.1 Gastrointestinal Drugs Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Cases of Gastrointestinal Diseases
- 5.2.2 Increasing Development of Biologics
5.3 Market Restraints
- 5.3.1 High Cost of Biologics
- 5.3.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Companies
5.5 Future Trends
- 5.5.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
5.6 Impact of Drivers and Restraints:

6. Gastrointestinal Drugs Market - Global Market Analysis

6.1 Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
6.2 Gastrointestinal Drugs Market Forecast Analysis

7. Gastrointestinal Drugs Market Analysis - by Drug Class

7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Antidiarrheal and Laxatives
- 7.2.1 Overview
- 7.2.2 Antidiarrheal and Laxatives: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Acid Neutralizers
- 7.3.1 Overview
- 7.3.2 Acid Neutralizers: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Anti-inflammatory Drugs
- 7.4.1 Overview
- 7.4.2 Anti-inflammatory Drugs: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Antiemetic and Antinauseants
- 7.5.1 Overview
- 7.5.2 Antiemetic and Antinauseants: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Gastrointestinal Drugs Market Analysis - by Application

8.1 Irritable Bowel Syndrome
- 8.1.1 Overview
- 8.1.2 Irritable Bowel Syndrome: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Inflammatory Ulcerative Colitis
- 8.2.1 Overview
- 8.2.2 Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Crohns Disease
- 8.3.1 Overview
- 8.3.2 Crohns Disease: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Gastroenteritis
- 8.4.1 Overview
- 8.4.2 Gastroenteritis: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Celiac Disease
- 8.5.1 Overview
- 8.5.2 Celiac Disease: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Gastrointestinal Drugs Market Analysis - by Route Of Administration

9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Parenteral
- 9.2.1 Overview
- 9.2.2 Parenteral: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Gastrointestinal Drugs Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. Gastrointestinal Drugs Market - Geographical Analysis

11.1 North America
- 11.1.1 North America Gastrointestinal Drugs Market Overview
- 11.1.2 North America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.1.2.1 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
  - 11.1.2.2 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
  - 11.1.2.3 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.1.2.4 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.1.3 North America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
  - 11.1.3.1 United States: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.1.1 United States: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.3.1.2 United States: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.3.1.3 United States: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.3.1.4 United States: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.1.3.2 Canada: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.2.1 Canada: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.3.2.2 Canada: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.3.2.3 Canada: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.3.2.4 Canada: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.1.3.3 Mexico: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.3.1 Mexico: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.3.3.2 Mexico: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.3.3.3 Mexico: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.3.3.4 Mexico: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.2 Europe
- 11.2.1 Europe Gastrointestinal Drugs Market Overview
- 11.2.2 Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.2.2.1 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
  - 11.2.2.2 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
  - 11.2.2.3 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.2.2.4 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.2.3 Europe: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
  - 11.2.3.1 Germany: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.1.1 Germany: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.2.3.1.2 Germany: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.2.3.1.3 Germany: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.2.3.1.4 Germany: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.2.3.2 United Kingdom: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.2.1 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.2.3.2.2 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.2.3.2.3 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.2.3.2.4 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.2.3.3 France: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.3.1 France: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.2.3.3.2 France: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.2.3.3.3 France: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.2.3.3.4 France: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.2.3.4 Italy: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.4.1 Italy: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.2.3.4.2 Italy: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.2.3.4.3 Italy: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.2.3.4.4 Italy: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.2.3.5 Spain: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.5.1 Spain: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.2.3.5.2 Spain: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.2.3.5.3 Spain: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.2.3.5.4 Spain: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.2.3.6 Rest of Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.6.1 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.2.3.6.2 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.2.3.6.3 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.2.3.6.4 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.3 Asia Pacific
- 11.3.1 Asia Pacific Gastrointestinal Drugs Market Overview
- 11.3.2 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.3.2.1 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
  - 11.3.2.2 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
  - 11.3.2.3 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.3.2.4 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.3.3 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
  - 11.3.3.1 China: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.1.1 China: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.3.3.1.2 China: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.3.3.1.3 China: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.3.3.1.4 China: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.3.3.2 Japan: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.1 Japan: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.3.3.2.2 Japan: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.3.3.2.3 Japan: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.3.3.2.4 Japan: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.3.3.3 India: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.1 India: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.3.3.3.2 India: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.3.3.3.3 India: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.3.3.3.4 India: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.3.3.4 Australia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.1 Australia: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.3.3.4.2 Australia: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.3.3.4.3 Australia: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.3.3.4.4 Australia: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.3.3.5 South Korea: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.1 South Korea: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.3.3.5.2 South Korea: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.3.3.5.3 South Korea: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.3.3.5.4 South Korea: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.3.3.6 Rest of APAC: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.1 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.3.3.6.2 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.3.3.6.3 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.3.3.6.4 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.4 Middle East & Africa
- 11.4.1 Middle East & Africa Gastrointestinal Drugs Market Overview
- 11.4.2 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.4.2.1 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
  - 11.4.2.2 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
  - 11.4.2.3 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.4.2.4 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.3 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
  - 11.4.3.1 Saudi Arabia: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.1.1 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.4.3.1.2 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.4.3.1.3 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.4.3.1.4 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.4.3.2 South Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.2.1 South Africa: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.4.3.2.2 South Africa: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.4.3.2.3 South Africa: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.4.3.2.4 South Africa: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.4.3.3 United Arab Emirates: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.3.1 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.4.3.3.2 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.4.3.3.3 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.4.3.3.4 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.4.3.4 Rest of Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.4.1 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.4.3.4.2 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.4.3.4.3 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.4.3.4.4 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.5 South & Central America
- 11.5.1 South & Central America Gastrointestinal Drugs Market Overview
- 11.5.2 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.5.2.1 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Drug Class
  - 11.5.2.2 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Application
  - 11.5.2.3 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.5.2.4 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.5.3 South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
  - 11.5.3.1 Brazil: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.1.1 Brazil: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.5.3.1.2 Brazil: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.5.3.1.3 Brazil: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.5.3.1.4 Brazil: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.5.3.2 Argentina: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.2.1 Argentina: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.5.3.2.2 Argentina: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.5.3.2.3 Argentina: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.5.3.2.4 Argentina: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.5.3.3 Rest of South & Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.3.1 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.5.3.3.2 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Application
    - 11.5.3.3.3 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.5.3.3.4 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Distribution Channel

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in Gastrointestinal Drugs Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Sanofi SA
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GSK Plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Johnson & Johnson
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bausch Health Companies Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 AstraZeneca Plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AbbVie Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bayer AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Celltrion Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Pfizer Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms